Ethereum (ETH/USD) closes above $3,500 per token on March 31, 2027
Pending
✦ AI-generated prediction
Published on 1. October 2026
·
Predicted for 31. March 2027
·
Based on: Speculative
Ethereum trades at $2,680 on Oct 1, 2026 (CoinGecko). The $3,500 threshold is 30.6% above current price — achievable within 6 months but ambitious. Forecaster consensus for October 2026 alone: DailyForex $2,600–$3,100; CoinDCX $2,950; Changelly $3,045–$3,070 (minimum target). The $3,500 level thus represents a natural projection of October momentum into Q1 2027. Bullish drivers: ETH staking yields remain attractive; Layer-2 adoption (Base, Arbitrum, Optimism) accelerates network utilization; historical BTC halving cycle patterns favor altcoin rallies from Q4 2026. Headwinds: US SEC regulatory action, macro-driven risk aversion, or decoupling from BTC. No direct Polymarket market found for this horizon; 30% probability conservatively derived from forecaster spread and ETH volatility profile.
Data basis for this prediction
- CoinGecko: ETH/USD 2.680 USD (1. Oktober 2026)
- DailyForex ETH Oktober-2026-Prognose: Spanne 2.600–3.100 USD (September 2026)
- CoinDCX ETH-Kursziel Oktober 2026: 2.950 USD; Changelly Minimum: 3.045 USD
- CoinGecko: BTC/USD 84.307 USD (1. Oktober 2026, Korrelations-Referenz)
Note: This is an AI-generated statistical forecast for entertainment and information purposes. It does not constitute investment advice or a recommendation to buy or sell any financial instrument.
Verdict: Pending
This prediction is still open. It will be evaluated automatically against real-world sources after its due date.
💻 Technology
✦ AI
The Royal Swedish Academy of Sciences announces the Nobel Prize in Chemistry on October 7. Shankar Balasubramanian and David Klenerman (both University of Cambridge) are the main favorites on small, illiquid prediction markets (Kalshi, Polymarket) for their invention of Sequencing by Synthesis (SBS), the foundation of modern NGS platforms — above all Illumina — which has revolutionized personalized medicine, oncology, and infectious disease epidemiology. Other strongly backed candidates: Pieter Cullis (UBC) for lipid nanoparticle technology (mRNA vaccines) and the skeletal editing trio Sarpong/Levin/Miranda. Kalshi: Balasubramanian/Klenerman as frontrunners without published exact odds; market positioning per Chemistry World and The Scientist implies approximately 20–28% for this duo. Nobel committees historically act surprisingly; probability set at 25%.
💻 Technology
✦ AI
TSMC posted a record August 2026 revenue of NT$514.806 billion (+53.3% YoY, +10.1% MoM). Cumulative Jan–Aug 2026 revenues: NT$3,386.87 billion (+39.3% YoY). Seasonal tailwinds from the Apple iPhone high season in September and sustained Nvidia/AMD orders support a similarly strong September figure. Estimated Sep-2025 base of NT$325–335 billion implies a +53% YoY September 2026 figure of ~NT$498–513 billion, making the NT$500 billion threshold approximately the median of that range. Headlines indicate another strong September ('can't keep up with demand'). No Polymarket price found for this specific threshold.
💻 Technology
✦ AI
ASML (NASDAQ/Euronext: ASML) guided Q3 2026 net sales to €11.0–12.0 billion at 55–57% gross margin. In Q2 2026 the company posted €9.3 billion net sales, beating guidance ('Q2 2026 beats guidance as AI demand lifts outlook'). Full-year 2026 guidance was raised to €43–45 billion net sales. Exceeding the guidance midpoint of €11.5 billion requires +23.7% sequential growth from Q2 — consistent with ASML's typical H2 seasonal strength driven by EUV system deliveries. Given the Q2 guidance beat and raised full-year outlook, a midpoint beat is plausible at ~62%. No specific Polymarket price found.